Pediatric Bioequivalence Studies Are Unnecessary, FDA Says In Rejecting Nycomed Petition
This article was originally published in The Pink Sheet Daily
Executive Summary
Nycomed had sought additional approval requirements for generic versions of its atopic dermatitis lotion Cutivate.
You may also be interested in...
FDA Reverses Stance On Bioequivalence Standards For Mesalamine
FDA believes that comparative pharmacokinetic studies, instead of comparative clinical endpoint studies, are best for determining bioequivalence of extended- or delayed-release mesalamine products - a reversal of its previous position
Lupin, Schering Settle Clarinex Patent Dispute; Glenmark, Nycomed Clash Over Cutivate
MUMBAI - Indian drug maker Lupin has settled all its patent litigations with Schering Plough and Sepracor over allergy drug Clarinex (desloratadine). According to the agreement, while the key Clarinex patent expires in 2020, Lupin will gain licenses under the relevant desloratadine patents and will be free to commercially launch its generic desloratadine on July 1, 2012, or earlier in certain circumstances
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.